1Larrey D, Erlinger S, Krishnasuamy K, et al. Hepatic dysfunction in undernourished patients receiving in soniazid and rifarnpicin[J]. Baillieres Clin Gastroenterol, 1998,23 (4):423-431
2Turktas H,Unsal M,Tulek N, et al. Hpatotoxicity of antituberculosis therapy (rifampicin, isoniazidand and pyrazinamide) or viral hepatitis [J]. Tuberc Lung Dis. 1994, 75(1): 58-60
3Miller MS, McCarver DC, Bell DA, et al. Toxic hepatitis with isoniazd and rifampin [J]. Fundam Appl Tocicol,1999,40(l)1-14
4Pessyre D, Bentata M, Degott C. Isoniazid-rifampin fulminant hepatitis: a possible consequence of enhancement of isoniazid hepatotoxicity by enzyme induction [J]. gasteoenterol, 1997,131(2): 284-292
5Kaplovitz N. Drug-induced liver disorders: implication for drug development and regulation [J]. Drug Sa f, 2001,24(2) :483-490
6Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury: mechanisms and test systerms [J]. Hepatology,2001,33(9): 1009-1013
7Zimmerman HJ. Drug-induced liver disease. In: Schiff ER,Sorrell MF, MaddreyWC, eds. Schiff' s diseases of the liver.New York: Lippincott-Raven, 1998. 973-1004
8Lewis JH. Drug-induced liver disease[J]. Med Clin North Am, 2000,84 (8): 1275 - 1371
9Anon G. Prevent rifarnpicin conbined with pyrazinamide induced liver function lesion[J]. Am J Nurs, 2001,101 (12):83-86
